Cordyceps and Asthma: Anti-Inflammatory Airway Effects

Cordyceps & Respiratory Health

1 human trial — randomised, never blinded

One randomized trial in moderate-to-severe asthma (120 patients, Cordyceps sinensis added to inhaled steroid therapy) reported better asthma quality of life, lung function and serum inflammatory markers. Its control group received no capsule at all — not a placebo — so nobody in the trial was blinded. Supporting rodent data show consistent Th2 cytokine suppression across four different cordyceps preparations.

Wang et al., Evidence-Based Complementary and Alternative Medicine, 2016

No placebo arm

the control group in the only human trial received nothing, so no one was blinded

Th2 cytokines

cordycepin reduces IL-4, IL-5, IL-13 and eotaxin in mouse BAL fluid

Beaten by steroids

C. militaris underperformed prednisolone and montelukast head-to-head in mice

Wang et al., Evidence-Based Complementary and Alternative Medicine, 2016

View as image ↗

Cordyceps has a long traditional use for respiratory conditions in Chinese medicine, and modern research has started to test this systematically for asthma. The claim is that cordyceps extracts, or the isolated nucleoside cordycepin, reduce airway inflammation through measurable anti-Th2 effects on cytokines, eosinophils and airway hyperreactivity. The evidence supporting this claim is mostly preclinical: several well-characterised rodent models of allergic asthma show clear effects, while human data is limited to a single randomised trial that, on close reading, was not placebo-controlled. This article examines what the asthma-specific cordyceps research actually shows, which preparation each finding belongs to, and where the gap between animal and human data is still open. For the broader respiratory picture, see cordyceps for lung health: what the research shows and cordyceps and COPD: can it improve breathing?.

Before you read further

Critical

Asthma is the wrong condition to experiment on

Concern

Moderate-to-severe asthma can kill quickly when controller therapy is reduced or stopped. Nothing in the cordyceps literature has ever tested it as a substitute for an inhaled corticosteroid, and the one head-to-head animal comparison found cordyceps clearly weaker than both prednisolone and montelukast.

What the research says

Every study described on this page either added cordyceps on top of standard asthma therapy or used it in animals that were not receiving any. There is no published evidence base for replacement, and no trial has measured what happens to exacerbation risk if controller medication is reduced.

Particularly relevant for: Anyone with diagnosed asthma, especially moderate-to-severe or steroid-dependent asthma

What to do

Do not change, taper or stop any prescribed inhaler or asthma medication based on this research. Discuss any supplement with the clinician managing your asthma, including because immune-modulating products may interact with your existing treatment. This article is research explanation, not medical advice.

Hsu et al., 2008 (PMID 19133568); Wang et al., 2016 (PMID 28050193)

Asthma Pathology the Research Targets

Allergic asthma is driven primarily by a Th2-biased adaptive immune response. The cytokines IL-4, IL-5 and IL-13 orchestrate IgE production, eosinophil recruitment, mucus hypersecretion and smooth muscle hyperresponsiveness. NF-κB and p38-MAPK are upstream signalling nodes that regulate transcription of these cytokines and of adhesion molecules such as ICAM-1 that bring inflammatory cells to the airway. Eotaxin is the specific chemokine that recruits eosinophils.

This is the pathway map against which cordyceps and cordycepin have been tested. A compound that measurably reduces IL-4, IL-5, IL-13, eotaxin and eosinophil counts in the airway while blocking NF-κB and p38-MAPK is intervening at the correct molecular targets. Whether it does so strongly enough, safely enough and reproducibly enough in humans to matter clinically is a separate question — and it is the question the evidence has not answered.

The One Human Trial, and What Its Control Group Actually Received

Wang et al. (2016), published in Evidence-Based Complementary and Alternative Medicine, randomized 120 patients with moderate-to-severe persistent asthma.^[1] Sixty received a Corbin capsule containing Cordyceps sinensis for three months. The other sixty, in the trial's own words, "did not receive treatment with Corbin capsule." There was no dummy capsule and no sham procedure. This is the single most important and most frequently misreported fact about the study: it was randomised, but it was not placebo-controlled, and nobody involved was blinded.

Both groups continued on inhaled corticosteroid and as-needed beta-agonists throughout. That detail is often lost too, and it cuts in the study's favour on one point and against it on another. In its favour: this was a genuine add-on design, so any benefit sits on top of proper controller therapy rather than replacing it. Against it: it means the trial can say nothing at all about cordyceps used alone.

Health-related quality of life was measured with Juniper's Asthma Quality of Life Questionnaire. Asthma exacerbation incidence, pulmonary function testing and serum inflammatory mediators were also evaluated. The treatment group showed significantly higher AQLQ scores and lung function than the control group, and its serum markers moved coherently: IgE, ICAM-1, IL-4 and MMP-9 all decreased while IgG increased.

The only human trial

Wang et al. (2016) · Evidence-Based Complementary and Alternative Medicine

Population

120 patients with moderate-to-severe persistent asthma; 60 treated, 60 control

Intervention

Corbin capsule containing Cordyceps sinensis for 3 months, on top of inhaled corticosteroid and as-needed beta-agonists

Comparator

No capsule at all — an untreated control arm, not a placebo. No blinding of patients or assessors.

Finding

Higher AQLQ scores and lung function versus control. Serum IgE, ICAM-1, IL-4 and MMP-9 decreased; IgG increased.

preliminary Registered as ChiCTR-IPC-16008730 and declaring no conflict of interest, but the absence of a placebo arm leaves the patient-reported primary endpoint wide open to expectation effects. The serum marker changes are the durable part of the result. No independent replication has been published.

Wang et al., Evidence-Based Complementary and Alternative Medicine, 2016 (PMID 28050193)

The missing placebo does not make the trial worthless, but it does mean its endpoints have to be read at different strengths. A patient who knows they were handed a capsule and a patient who knows they were handed nothing are not answering the same questionnaire. Serum IL-4, by contrast, does not care what anyone believes.

Randomised — but not placebo-controlled

What the Control Group in the Only Human Trial Actually Received

Wang et al. 2016 is almost always described as placebo-controlled. It was not. The control arm “did not receive treatment with Corbin capsule” — no dummy capsule, no sham. Nobody was blinded. That does not make the trial worthless; it makes some of its endpoints much stronger than others. Read them separately.

Treatment arm (n = 60)

Corbin capsule containing Cordyceps sinensis, 3 months+ inhaled corticosteroid + as-needed β-agonist

Control arm (n = 60)

No Corbin capsule — and no placebo capsule either+ inhaled corticosteroid + as-needed β-agonist

Both arms stayed on standard controller therapy. This was cordyceps added to an inhaled steroid, never tested as a substitute for one.

Health-related quality of life

Blinding-dependent

Measured by: Juniper's AQLQ — patient-completed questionnaire

Reported: Significant increase vs control

Entirely self-reported. A patient who knows they were given the capsule, and a patient who knows they were given nothing, are answering two different questions.

Asthma symptoms

Blinding-dependent

Measured by: Patient-reported symptom burden

Reported: Reported as improved

Same problem. Symptom perception in asthma is famously responsive to expectation, which is why asthma trials are normally sham-controlled.

Lung function

Partly exposed

Measured by: Pulmonary function testing

Reported: Significant increase vs control

Instrument-measured, but spirometry is effort-dependent and the technician was not blinded either. Harder to move by belief than a questionnaire, not immune to it.

Serum IgE, ICAM-1, IL-4, MMP-9

Survives unblinding

Measured by: Laboratory assay of serum inflammatory mediators

Reported: All four decreased vs control

A patient cannot will their serum IL-4 down because they know they got the capsule. This is the part of the trial that the missing placebo does not touch.

Serum IgG

Survives unblinding

Measured by: Laboratory assay

Reported: Increased vs control

Same reasoning. Objective biochemistry, independent of expectation.

The honest reading: the headline result — “cordyceps improved asthma quality of life” — rests on the endpoint most vulnerable to the missing placebo. The finding that deserves follow-up is the quieter one, that four serum inflammatory markers moved in the direction the mouse mechanism predicts. One unblinded trial cannot settle this either way. It can justify running the blinded one.

Source: Wang et al., Evidence-Based Complementary and Alternative Medicine, 2016 (RTHM-00838, PMID 28050193, ChiCTR-IPC-16008730). Endpoint list and results as reported in the published abstract; the blinding-exposure rating is this article’s assessment, not the trial authors’.

Two further limitations matter. The Corbin capsule's extract composition and cordycepin content are not characterised in the published abstract, so even a well-funded replication attempt would have to guess at what it was replicating. And three months speaks to neither long-term safety nor durability of effect.

The Preclinical Foundation

Yang et al. (2015) provides the most mechanistically detailed work in the file.^[2] Using the ovalbumin sensitisation-and-challenge mouse model, the researchers tested cordycepin at 10, 20 and 40 mg/kg and measured airway hyperresponsiveness, bronchoalveolar lavage cell counts and cytokines, serum IgE and lung tissue signalling. Cordycepin attenuated airway hyperresponsiveness and mucus hypersecretion, lowered ovalbumin-specific IgE, and reduced eosinophils and macrophages in BAL fluid. It reduced eotaxin, ICAM-1, IL-4, IL-5 and IL-13, and markedly blocked activation of the p38-MAPK and NF-κB pathways. Every node in the allergic asthma cascade moved in the expected direction.

The caveats are real. This is a purified compound rather than anything sold as a supplement, and the published abstract does not state the route of administration, so no oral-dose equivalence can be read off it.

Hsu et al. (2008) tested whole Cordyceps militaris rather than isolated cordycepin, and it deserves more weight than it usually gets because it is the only study here that ran proper positive controls.^[3] Sensitised BALB/c mice received C. militaris, prednisolone, montelukast or placebo by gavage from Days 15 to 27. Prednisolone and montelukast inhibited the airway inflammatory response; C. militaris "reduced airway inflammation less effectively." It initially reversed airway hyperreactivity, but that effect disappeared at higher methacholine doses. The authors' own conclusion is unusually blunt for this literature: C. militaris "is unable to adequately block the potent mediators of asthmatic airway inflammation."

That is a finding, not a footnote. The asthma literature is not claiming cordyceps matches inhaled corticosteroids or leukotriene antagonists. When someone ran the comparison directly, cordyceps lost.

Song et al. (2023) changes the shape of the argument.^[4] Rather than cordycepin, this group isolated and purified a Cordyceps militaris polysaccharide — an α-pyranose of 15.94 kDa composed of glucose, mannose, galactose, xylose, arabinose and glucuronic acid in a characterised molar ratio — and tested it in ovalbumin-induced allergic asthma mice. It improved inflammatory cytokine levels and lung and intestinal histopathology, acted through the Nrf2/HO-1 and NF-κB signalling pathways, and reversed gut dysbiosis at the phylum and family levels. Lung cytokine levels correlated significantly with intestinal microbial communities. No cordycepin was administered at any point.

Chen et al. (2020) tested a third kind of preparation: Cs-4, a water extract of Cordyceps sinensis mycelium culture, in a rat asthma model alongside a mouse allergic rhinitis model.^[5] Cs-4 decreased airway responsiveness, reduced plasma and BAL IgE and eosinophil peroxidase, and completely suppressed the increases in IL-4, IL-5 and IL-13 in rat lung tissue. This is directly relevant to the consumer market, because cultivated mycelium is what many commercial cordyceps products actually contain. It also carries a disclosure worth stating plainly: the work was funded by Royal Medic Group Holding Limited, which also supplied one of the co-authors.

Phull et al. (2022) sits at a different altitude — a review positioning Cordyceps militaris as an anti-inflammatory functional food, covering inflammatory conditions including cancer, colitis and allergies, with regulation of proinflammatory cytokines as the recurring theme.^[6] Its usefulness here is contextual rather than asthma-specific: cordyceps affects a general inflammatory pathway that happens to be the pathway driving allergic asthma.

Five substances, two species, one human trial

“Cordyceps for Asthma” Is Five Different Experiments

The asthma literature does not test a mushroom. It tests an isolated nucleoside, a cultivated fruiting-body extract, a purified polysaccharide, a mycelium culture broth, and a proprietary capsule — across two species that differ in chemistry. Findings do not transfer between rows, and a supplement bought off a shelf is none of these.

Cordycepin (isolated nucleoside)

from C. militarisMouse only

Tested in: Ovalbumin-driven asthmatic mice, 10 / 20 / 40 mg/kg (Yang 2015)

Found: Attenuated airway hyperresponsiveness and mucus hypersecretion; lowered OVA-specific IgE; fewer BAL eosinophils and macrophages; reduced eotaxin, ICAM-1, IL-4, IL-5, IL-13; blocked p38-MAPK and NF-κB activation

What it cannot carry: Purified compound, not a supplement. The abstract does not state the route of administration, so no oral-dose equivalence can be read off it.

Whole cultivated extract

C. militarisMouse — underperformed

Tested in: OVA mice, oral gavage Days 15–27, vs prednisolone, montelukast and placebo (Hsu 2008)

Found: Reduced airway inflammation and initially reversed airway hyperreactivity

What it cannot carry: The clearest negative result in the file: less effective than both standard drugs, and the hyperreactivity benefit "disappeared at higher methacholine doses." The authors conclude it "is unable to adequately block the potent mediators of asthmatic airway inflammation."

Purified polysaccharide (CMP)

C. militarisMouse only

Tested in: OVA allergic asthma mice; 15.94 kDa α-pyranose, six-sugar composition characterised (Song 2023)

Found: Improved inflammatory cytokines and lung + intestinal histopathology via Nrf2/HO-1 and NF-κB; reversed gut dysbiosis, with lung cytokines correlating to intestinal microbial communities

What it cannot carry: A different active fraction and a different mechanism from the cordycepin story — no cordycepin required. Mouse only, and correlation between gut flora and lung cytokines is not proof of causation.

Cs-4 mycelium culture extract

C. sinensisRodent — industry funded

Tested in: Rat asthma model plus mouse allergic rhinitis model (Chen 2020)

Found: Decreased airway responsiveness; lowered plasma and BAL IgE and eosinophil peroxidase; "completely suppressed" the rise in IL-4, IL-5 and IL-13 in rat lung tissue

What it cannot carry: Funded by Royal Medic Group Holding Limited, which also supplied a co-author — an industry-funded result on the company’s own class of product. Rodent only.

Corbin capsule (proprietary)

C. sinensisHuman — unblinded

Tested in: 120 moderate-to-severe asthma patients, 3 months, added to inhaled steroid (Wang 2016)

Found: Higher AQLQ scores and lung function; serum IgE, ICAM-1, IL-4 and MMP-9 down, IgG up

What it cannot carry: The only human data. Randomised but unblinded — the control arm received nothing at all. Extract composition and cordycepin content are not characterised in the published abstract.

Two of the five rows are the same species. None of the five is the capsule on a shop shelf. The one row with human data used a proprietary formulation whose composition was never published, which means even a perfect replication attempt would have to guess at what to replicate.

Sources: Yang et al., 2015 (RTHM-00750, PMID 25912153); Hsu et al., 2008 (RTHM-00254, PMID 19133568); Song et al., 2023 (RTHM-02445, PMID 37030458); Chen et al., 2020 (RTHM-02444, PMID 32899766); Wang et al., 2016 (RTHM-00838, PMID 28050193).

The Cordycepin Bioavailability Problem

Cordycepin (3'-deoxyadenosine) is the single most studied bioactive in Cordyceps militaris, with strong anti-inflammatory, anti-tumour and antiviral activity in cell culture and animal models. Its translation to oral human use runs into a specific pharmacokinetic obstacle. Chen et al. (2023) reviewed the problem: cordycepin undergoes rapid deamination by adenosine deaminase in vivo, which shortens its half-life and decreases its bioavailability.^[7] The review identifies three routes around it — co-administering an ADA inhibitor, developing structurally modified derivatives that resist deamination, and applying new drug delivery systems.

The obvious conclusion is that oral cordyceps faces a real pharmacokinetic headwind. But the obvious conclusion sits awkwardly beside the animal data, because three of the four positive asthma-model results used whole preparations given by mouth — and one of them contained no cordycepin at all.

A contradiction worth naming

If Oral Cordycepin Barely Survives, Why Do Oral Preparations Still Work?

The objection

Cordycepin undergoes rapid deamination by adenosine deaminase in vivo, shortening its half-life and cutting bioavailability. On that basis, a swallowed cordyceps capsule should not deliver a meaningful systemic dose.Chen 2023

The observation

Hsu 2008 dosed whole C. militaris by gavage. Song 2023 and Chen 2020 dosed a polysaccharide and a mycelium extract. All three reported airway effects anyway.Hsu 2008 · Song 2023 · Chen 2020

Both statements are well supported, so one of the unstated assumptions joining them must be wrong. The likeliest culprit is the assumption that cordycepin is the active ingredient. Here is what the record can and cannot back:

The polysaccharide, not the nucleoside, may be doing the work

Directly tested

Song 2023 got a full anti-asthmatic result from a purified 15.94 kDa C. militaris polysaccharide. No cordycepin was administered. If a polysaccharide can suppress the same pathways, cordycepin pharmacokinetics stop being the rate-limiting question.

The effect may start in the gut, not the bloodstream

Suggestive, not causal

Song 2023 reported reversal of gut dysbiosis and a significant correlation between intestinal microbial communities and lung inflammatory cytokines. A large polysaccharide that is never absorbed intact could still change airway immunology through the gut. Correlation, though — not demonstrated causation.

Cordycepin’s breakdown product is not necessarily inert at the airway

Untested hypothesis

Yue 2008 found that cordycepin and adenosine both stimulated ion transport in Calu-3 airway epithelial cells. Adenosine deaminase converts cordycepin to a deaminated analogue; the assumption that this abolishes all airway-relevant activity has not been tested in an asthma model.

This matters commercially as well as scientifically. Products are marketed on cordycepin content, and extraction methods are optimised for it. If the polysaccharide fraction is carrying the airway effect, then the number printed on the label is measuring the wrong molecule. Nobody has run the experiment that would settle it: a head-to-head of cordycepin against the polysaccharide fraction in the same asthma model.

Sources: Chen et al., 2023 (RTHM-01672, PMID 37329165); Hsu et al., 2008 (RTHM-00254, PMID 19133568); Song et al., 2023 (RTHM-02445, PMID 37030458); Chen et al., 2020 (RTHM-02444, PMID 32899766); Yue et al., 2008 (RTHM-02439, PMID 18358654).

The resolution most consistent with the published record is that cordycepin may simply not be the ingredient carrying the airway effect. Song's polysaccharide result is the strongest evidence for this, because it produced the same pathway-level outcome with a completely different molecule. If that is right, the industry convention of grading cordyceps products by cordycepin content is measuring the wrong thing for this particular use.

Cordyceps sinensis vs. Cordyceps militaris

The two species studied in asthma are pharmacologically distinct. Cordyceps sinensis (now classified as Ophiocordyceps sinensis) carries a complex polysaccharide profile with lower cordycepin content. Cordyceps militaris carries higher cordycepin concentrations and is the species behind most cordycepin-focused preclinical work. The asthma research uses both, in five different forms: Wang 2016 used a C. sinensis capsule, Chen 2020 used C. sinensis mycelium culture extract, Hsu 2008 used whole C. militaris, Song 2023 used a purified C. militaris polysaccharide, and Yang 2015 used isolated cordycepin.

This heterogeneity is a genuine interpretive problem rather than a technicality. Consumer cordyceps products differ by species, by fruiting body versus cultivated mycelium, by extraction method, and by cordycepin and polysaccharide content. Extrapolating from any one row of that table to a generic supplement is not straightforward, and extrapolating from the Wang trial in particular is hardest of all, because its formulation was never characterised publicly.

Airway Epithelial Ion Transport as a Secondary Mechanism

Beyond the Th2 cytokine story, cordyceps has been tested on airway epithelial function directly. Yue et al. (2008) applied Cordyceps sinensis and Cordyceps militaris extracts, and their isolated compounds cordycepin and adenosine, to Calu-3 human airway epithelial monolayers.^[8] All of them stimulated ion transport in a dose-dependent manner. Follow-up experiments using the transport inhibitor bumetanide and the carbonic anhydrase inhibitor acetazolamide indicated that the extracts affect anion movement from the basolateral to the apical compartment, with the basolateral Na⁺-K⁺-2Cl⁻ cotransporter and the apical cAMP-dependent CFTR chloride channel both involved. The authors describe this as the first evidence for a pharmacological mechanism of these species on the respiratory tract.

Anion secretion across the airway epithelium governs airway surface liquid volume, which in turn sets how efficiently the mucociliary escalator can clear secretions. It is worth being precise about what this does and does not say. It is a cell-culture result about hydration of the airway surface, not about mucus production — a distinction that matters, since Yang's mouse work found cordycepin reduced mucus hypersecretion. No study has tested whether the Calu-3 effect produces any clinical benefit in asthma, and the two findings have never been measured in the same experiment.

The mechanism is nonetheless worth noting because it is largely independent of Th2 immunology. A cordyceps effect on asthma could plausibly operate through reduced airway inflammation, improved epithelial hydration, or the gut-immune route Song's polysaccharide work points at — with the relative contribution of each in humans entirely unknown.

What the Evidence Does and Does Not Support

The cordyceps asthma evidence supports several specific claims. Cordycepin, whole Cordyceps militaris, a purified C. militaris polysaccharide and a C. sinensis mycelium extract each have measurable anti-inflammatory activity in rodent models of allergic asthma, reducing Th2 cytokines, airway eosinophils and hyperreactivity. A Cordyceps sinensis capsule improved quality-of-life, lung function and serum inflammatory markers in one 120-patient randomised trial, added on top of inhaled corticosteroid therapy. The molecular mechanism involves NF-κB and p38-MAPK suppression, with Nrf2/HO-1 signalling implicated for the polysaccharide fraction.

The evidence does not support several broader claims. There is no evidence that cordyceps matches or substitutes for inhaled corticosteroids or leukotriene antagonists — the only direct comparison found the opposite. There is no evidence that cordyceps is sufficient as monotherapy for moderate or severe asthma; it has never been tested that way. There is no blinded human trial, no independent replication, no head-to-head comparison of species or preparations in humans, and no long-term safety data beyond three months.

Evidence position

1. Cell studiescompleted

   Yue 2008 — Calu-3 human airway epithelia; both species and both isolated compounds stimulate anion transport via NKCC1 and CFTR

2. Animal modelscompleted

   Four independent rodent studies across four different preparations; consistent Th2 cytokine and IgE suppression, but the one study with positive controls found cordyceps weaker than prednisolone and montelukast

3. Case reportsmissing

   No published asthma case series for cordyceps

4. Small human trialcurrent

   Wang 2016 — 120 patients, randomised, add-on to inhaled steroid, but with an untreated rather than placebo control and no blinding

5. Large blinded RCTmissing

   No placebo-controlled trial of any cordyceps preparation in asthma has been published

6. Meta-analysismissing

   Impossible with a single unreplicated trial

The preclinical rungs are unusually well populated for a traditional-medicine claim, and the mechanistic work targets the right pathways. The human rung holds one unblinded trial of an uncharacterised proprietary capsule. Nothing above it exists. That combination justifies running a proper blinded trial; it does not justify a clinical recommendation.

Yue et al., 2008; Hsu et al., 2008; Yang et al., 2015; Chen et al., 2020; Song et al., 2023; Wang et al., 2016

Practical Interpretation of the Evidence

The cordyceps and asthma literature sits in a specific evidentiary position, and it is not the usual one. The preclinical data is better than for many traditional medicine claims, because the rodent allergic asthma model is rigorous and quantitative and the measured effects hit the correct molecular targets across four independent preparations. The human data is weaker than for approved asthma therapies, because it consists of one unblinded trial. This is not the familiar pattern where preclinical hype outruns clinical reality. It is closer to the reverse: coherent mechanistic work that has received almost no serious clinical testing.

The honest summary is that the field has earned a proper trial and has not yet run one. Meanwhile, consumer cordyceps products vary substantially in species, form, extraction method and compound content. No published study has tested whether any off-the-shelf cordyceps product reproduces the Wang trial result, and because that trial's formulation was never characterised, no product can legitimately claim to match it.

Research Gaps Worth Monitoring

Four gaps are specifically open. First, and most fixable, no placebo-controlled blinded trial has been run — the existing trial already established the add-on-to-inhaled-steroid design, so the obvious next study is the same design with a dummy capsule. Second, no head-to-head trial of C. sinensis against C. militaris in asthma has been conducted, despite these being materially different preparations. Third, no experiment has compared cordycepin against the polysaccharide fraction in the same asthma model, which is the study that would settle which molecule the industry should be standardising on. Fourth, oral cordycepin pharmacokinetics in humans have not been comprehensively characterised, so the optimal exposure for respiratory anti-inflammatory activity remains unknown.

For the related respiratory performance question, see cordyceps and high-altitude performance: the Tibetan tradition meets modern science and cordyceps and oxygen utilization at high altitude. The high-altitude and exercise literature uses different endpoints and different cordyceps preparations, but shares the underlying question of whether systemic cordyceps exposure meaningfully affects pulmonary and oxygen-delivery physiology.

The Bottom Line

Cordyceps preparations show reproducible anti-inflammatory activity in rodent models of allergic asthma, reducing Th2 cytokines, airway eosinophils, IgE and hyperresponsiveness, and suppressing NF-κB and p38-MAPK signalling. Four different preparations have produced this pattern — isolated cordycepin, whole Cordyceps militaris, a purified C. militaris polysaccharide, and a C. sinensis mycelium extract — which suggests the active fraction may not be cordycepin at all. The human evidence is one 120-patient randomised trial of a Cordyceps sinensis capsule added to inhaled steroid therapy, and its control group received no capsule rather than a placebo, leaving the patient-reported quality-of-life result exposed to expectation effects while the serum marker changes stand up better. The only direct comparison against standard drugs found cordyceps less effective than prednisolone and montelukast. Nothing in this literature supports using cordyceps in place of prescribed asthma therapy.

Frequently Asked Questions

Can cordyceps help with asthma?

One randomized trial (Wang et al., 2016, 120 patients) reported that a Cordyceps sinensis capsule taken for three months alongside standard inhaled steroid therapy improved asthma quality of life, lung function and serum inflammatory markers compared with a control group. The important caveat is that the control group received no capsule at all rather than a placebo, so nobody was blinded and the quality-of-life finding is vulnerable to expectation effects. Rodent data supports the underlying anti-inflammatory mechanism, but no blinded trial and no independent replication has been published.

Was the cordyceps asthma trial placebo-controlled?

No, although it is frequently described that way. Wang et al. (2016) randomized 120 patients, but the control arm "did not receive treatment with Corbin capsule" — there was no dummy capsule and no sham. Randomisation without blinding still protects against selection bias, but it does not protect a patient-completed questionnaire from expectation effects. The trial's serum measurements of IgE, ICAM-1, IL-4, MMP-9 and IgG are the findings least affected by the missing placebo.

How does cordycepin reduce airway inflammation?

Yang et al. (2015) showed cordycepin reduces IL-4, IL-5, IL-13, eotaxin and ICAM-1 in the bronchoalveolar lavage fluid of asthmatic mice, lowers eosinophil and macrophage counts, decreases ovalbumin-specific IgE, and blocks activation of p38-MAPK and NF-κB signalling. These are the canonical Th2-driven asthma pathways, and cordycepin intervenes at multiple nodes simultaneously.

Is cordyceps as effective as inhaled corticosteroids for asthma?

No. Hsu et al. (2008) compared Cordyceps militaris directly against prednisolone and montelukast in a mouse asthma model and found it reduced airway inflammation less effectively than either, with its effect on airway hyperreactivity disappearing at higher methacholine doses. The authors concluded it "is unable to adequately block the potent mediators of asthmatic airway inflammation." No human trial has tested cordyceps as a replacement for controller therapy, and the evidence does not support using it as monotherapy for moderate or severe asthma.

What is the difference between Cordyceps sinensis and Cordyceps militaris for asthma?

Cordyceps sinensis (Ophiocordyceps sinensis) has lower cordycepin content and a different polysaccharide profile; it was the species used in the Wang et al. (2016) human trial and in the Cs-4 mycelium extract tested by Chen et al. (2020). Cordyceps militaris has higher cordycepin content and is the species behind most preclinical mechanistic work, including Yang et al. (2015) and Song et al. (2023). No head-to-head human comparison for asthma has been published.

Is cordycepin actually the active ingredient for asthma?

It may not be. Song et al. (2023) produced a full anti-asthmatic result in mice using a purified Cordyceps militaris polysaccharide with no cordycepin administered, acting through Nrf2/HO-1 and NF-κB pathways and reversing gut dysbiosis. Combined with the fact that most positive animal results used whole preparations given by mouth despite cordycepin's poor oral bioavailability, this suggests the polysaccharide fraction may be doing significant work. No study has compared the two fractions head-to-head in the same asthma model.

Why is cordycepin not more widely used clinically?

Chen et al. (2023) identified the primary problem: cordycepin is rapidly deaminated in vivo by adenosine deaminase, shortening its half-life and reducing its bioavailability. The review names three strategies under investigation — co-administering an ADA inhibitor, developing deamination-resistant derivatives through structural modification, and applying new drug delivery systems — none of which has yet produced a clinically deployable oral cordycepin product.

Does cordyceps reduce IgE levels?

Reduced IgE has been reported in both the animal work and the one human trial. Yang et al. (2015) showed lowered ovalbumin-specific IgE in mice, Chen et al. (2020) reported reduced plasma and bronchoalveolar IgE in rats, and Wang et al. (2016) reported decreased serum IgE in patients taking Cordyceps sinensis versus an untreated control group. The mechanism appears to involve Th2 cytokine suppression, particularly of IL-4, which drives IgE class-switching.

Sources & References

1. 1RTHM-00456·Wang, Ningqun et al. (2016). “Herbal Medicine Cordyceps sinensis Improves Health-Related Quality of Life in Moderate-to-Severe Asthma..” Evidence-based complementary and alternative medicine : eCAM.Study breakdown →PubMed →↩
2. 2RTHM-00411·Yang, Xiaofeng et al. (2015). “Cordycepin alleviates airway hyperreactivity in a murine model of asthma by attenuating the inflammatory process..” International immunopharmacology.Study breakdown →PubMed →↩
3. 3RTHM-00136·Hsu, Chia-Hsiu et al. (2008). “Effects of the immunomodulatory agent Cordyceps militaris on airway inflammation in a mouse asthma model..” Pediatrics and neonatology.Study breakdown →PubMed →↩
4. 4RTHM-02445·Song, Lanyue et al. (2023). “Cordyceps militaris polysaccharide alleviates ovalbumin-induced allergic asthma through the Nrf2/HO-1 and NF-κB signaling pathways and regulates the gut microbiota..” International journal of biological macromolecules.Study breakdown →PubMed →↩
5. 5RTHM-02444·Chen, Jihang et al. (2020). “Anti-Inflammatory Effects of a Cordyceps sinensis Mycelium Culture Extract (Cs-4) on Rodent Models of Allergic Rhinitis and Asthma..” Molecules.Study breakdown →PubMed →↩
6. 6RTHM-00790·Phull, Abdul-Rehman et al. (2022). “Cordyceps militaris as a Bio Functional Food Source: Pharmacological Potential, Anti-Inflammatory Actions and Related Molecular Mechanisms..” Microorganisms.Study breakdown →PubMed →↩
7. 7RTHM-00817·Chen, Min et al. (2023). “Cordycepin: A review of strategies to improve the bioavailability and efficacy..” Phytotherapy research : PTR.Study breakdown →PubMed →↩
8. 8RTHM-02439·Yue, Grace Gar-Lee et al. (2008). “Effects of Cordyceps sinensis, Cordyceps militaris and their isolated compounds on ion transport in Calu-3 human airway epithelial cells..” Journal of ethnopharmacology.Study breakdown →PubMed →↩